Beta-blocker use in severe sepsis and septic shock: A systematic review

Current Medical Research and Opinion

Volumn 31, Issue 10, 2015, Pages 1817-1825

  Sanfilippo, Filippo ^a   Santonocito, Cristina ^b   Morelli, Andrea ^c   Foex, Pierre ^d  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Critical care; Esmolol; Hemodynamics; Infection; Intensive care; Systemic Inflammatory Response Syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; DIGITALIS; ESMOLOL; GLUCAGON; LACTIC ACID; METOPROLOL; MILRINONE; NORADRENALIN; STEROID; PROPANOLAMINE DERIVATIVE;

ALKALOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DRUG USE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MORTALITY; NONHUMAN; PH; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; TACHYCARDIA; ANIMAL; DRUG EFFECTS; SHOCK, SEPTIC;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HEART RATE; HEMODYNAMICS; HUMANS; METOPROLOL; PROPANOLAMINES; SEPSIS; SHOCK, SEPTIC;

EID: 84942295273     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1062357     Document Type: Review

References (67)

1. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011;123:2434-506
2. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
3. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
4. Sanfilippo F, Santonocito C, Foex P. Use of beta-blockers in non-cardiac surgery: an open debate. Minerva Anestesiologica 2014;80:482-94
5. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:77-137
6. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA guidelines on noncardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383-431
7. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53
8. Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed) 2009;339:b2700
10. Sanfilippo F, Santonocito C, Maybauer MO. Short-acting beta-blocker administration in patients with septic shock. JAMA 2014;311:736
11. Yang S, Liu Z, Yang W, et al. [Effects of the beta-blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study]. Zhonghua wei zhong bing ji jiu yi xue 2014;26:714-17
12. Morelli A, Donati A, Ertmer C, et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8
13. Balik M, Rulisek J, Leden P, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Wiener Klinische Wochenschrift 2012;124:552-6
14. Morelli A, D'Egidio A, Orecchioni A, et al. Heart rate reduction with esmolol in septic shock: effects on myocardial performance. Crit Care 2014;18(Suppl 1):P162
15. Schmittinger CA, Dunser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care (London, England) 2008;12:R99
16. Gutierrez J, Hossam A, Lazarezcu R, et al. Effect of beta blockers on sepsis outcome. Med Sci Mon Int Med J Exp Clin Res 2009;15:CR499-503
17. Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg (Chicago, Ill 1960) 1972;104:46-51
18. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970;130:1025-34
19. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006;139:686-94
20. Sander O, Welters ID, Foex P, Sear JW. Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 2005;33:81-8; discussion 241-2
21. Vellinga NA, Boerma EC, Koopmans M, et al. International study on microcirculatory shock occurrence in acutely ill patients. Crit Care Med 2015;43:48-56
22. Mori K, Morisaki H, Yajima S, et al. Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. Intensive Care Med 2011;37:1849-56
23. Ibrahim-Zada I, Rhee P, Gomez CT, et al. Inhibition of sepsis-induced inflammatory response by beta1-adrenergic antagonists. J Trauma Acute Care Surg 2014;76:320-8
24. Ackland GL, Yao ST, Rudiger A, et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010;38:388-94
25. Macchia A, Romero M, Comignani PD, et al. Previous prescription of betablockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis. Crit Care Med 2012;40:2768-72
26. Christensen S, Johansen MB, Tonnesen E, et al. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit Care (London, England) 2011;15:R87
27. Nuding S, Ebelt H, Hoke RS, et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol 2011;100:915-23
28. Furian T, Aguiar C, Prado K, et al. Ventricular dysfunction and dilation in severe sepsis and septic shock: relation to endothelial function and mortality. J Crit Care 2012;27:319 e9-15
29. Brown SM, Pittman JE, Hirshberg EL, et al. Diastolic dysfunction and mortality in early severe sepsis and septic shock: a prospective, observational echocardiography study. Crit Ultrasound J 2012;4:8
30. Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012;33:895-903
31. Pulido JN, Afessa B, Masaki M, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock. Mayo Clin Proc 2012;87:620-8
32. Huang SJ, Nalos M, McLean AS. Is early ventricular dysfunction or dilatation associated with lower mortality rate in adult severe sepsis and septic shock? A meta-analysis. Crit Care (London, England) 2013;17:R96
33. Sanfilippo F, Corredor C, Fletcher N, et al. Erratum to: Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis. Intensive Care Med 2015;41:1178-9
34. Sanfilippo F, Corredor C, Fletcher N, et al. Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis. Intensive Care Med 2015;41:1004-13
35. Bergstrom A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-61
36. Wang JF, Meissner A, Malek S, et al. Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol 2005;289:H1577-83
37. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-48
38. O'Dwyer MJ, Mankan AK, Stordeur P, et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock (Augusta, Ga) 2006;26:544-50
39. Cavaillon JM, Adib-Conquy M, Fitting C, et al. Cytokine cascade in sepsis. Scand J Infect Dis 2003;35:535-44
40. Gullo A, Foti A, Murabito P, et al. Spectrum of sepsis, mediators, source control and management of bundles. Front Biosci (Elite edition) 2010;2:906-11
41. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999;27:1309-18
42. Hsueh WA, Law R. The central role of fat and effect of peroxisome proliferatoractivated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 2003;92:3-9J
43. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care (London, England) 2009;13:230
44. Suzuki T, Morisaki H, Serita R, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301
45. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock (Augusta, Ga) 2009;31:515-20
46. Calzavacca P, Lankadeva YR, Bailey SR, et al. Effects of selective ss1-adrenoceptor blockade on cardiovascular and renal function and circulating cytokines in ovine hyperdynamic sepsis. Crit Care (London, England) 2014;18:610
47. Lang CH, Nystrom G, Frost RA. Beta-adrenergic blockade exacerbates sepsisinduced changes in tumor necrosis factor alpha and interleukin-6 in skeletal muscle and is associated with impaired translation initiation. J Trauma 2008;64:477-86
48. Oberbeck R, Schmitz D, Wilsenack K, et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 2004;11:214-23
49. Schmitz D, Wilsenack K, Lendemanns S, et al. beta-Adrenergic blockade during systemic inflammation: impact on cellular immune functions and survival in a murine model of sepsis. Resuscitation 2007;72:286-94
50. Giebelen IA, Leendertse M, Dessing MC, et al. Endogenous beta-adrenergic receptors inhibit lipopolysaccharide-induced pulmonary cytokine release and coagulation. Am J Respir Cell Mol Biol 2008;39:373-9
51. Muthu K, He LK, Szilagyi A, et al. Propranolol restores the tumor necrosis factor-alpha response of circulating inflammatory monocytes and granulocytes after burn injury and sepsis. J Burn Care Res 2009;30:8-18
52. Muthu K, Deng J, Gamelli R, et al. Adrenergic modulation of cytokine release in bone marrow progenitor-derived macrophage following polymicrobial sepsis. J Neuroimmunol 2005;158:50-7
53. Deng J, Muthu K, Gamelli R, et al. Adrenergic modulation of splenic macrophage cytokine release in polymicrobial sepsis. Am J Physiol Cell Physiol 2004;287:C730-6
54. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-12
55. Plank LD, Connolly AB, Hill GL. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg 1998;228:146-58
56. Trager K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 2003;9:271-8
57. Lang CH. Sepsis-induced insulin resistance in rats is mediated by a betaadrenergic mechanism. Am J Physiol 1992;263(4 Pt 1):E703-11
58. Chu CA, Sindelar DK, Igawa K, et al. The direct effects of catecholamines on hepatic glucose production occur via alpha(1)-and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metabol 2000;279:E463-73
59. Tappy L, Chiolero R. Substrate utilization in sepsis and multiple organ failure. Crit Care Med 2007;35(9 Suppl):S531-4
60. Levy B, Desebbe O, Montemont C, Gibot S. Increased aerobic glycolysis through beta2 stimulation is a common mechanism involved in lactate formation during shock states. Shock (Augusta, Ga) 2008;30:417-21
61. Jeschke MG, Norbury WB, Finnerty CC, et al. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma 2007;62:676-81
62. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukocyte Biol 2008;83:536-45
63. von Kanel R, Dimsdale JE, Adler KA, et al. Effects of nonspecific beta-adrenergic stimulation and blockade on blood coagulation in hypertension. J Applied Physiol (Bethesda, Md: 1985) 2003;94:1455-9
64. Boman K, Boman JH, Andersson J, et al. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy. Clin Appl Thromb Hemost 2010;16:146-52
65. Markel A, Brook JG, Levy Y, et al. Increased platelet adhesion and aggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol 1983;16:663-8
66. Horn EH, Jalihal S, Bruce M, et al. The effect on platelet behaviour of treatment with atenolol and the combination of atenolol and nifedipine in healthy volunteers. Platelets 1992;3:15-21
67. Gleerup G, Mehlsen J, Winther K. Does calcium channel blockade and betaadrenergic blockade affect platelet function and fibrinolysis to a varying degree? J Cardiovasc Pharmacol 1995;25:87-9